GT Biopharma, Inc. (GTBP) - 10-Q Summary for Period Ended June 30, 2025
Business Context and Reporting Period
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company developing immune-oncology products based on its proprietary Tri-specific Killer Engager (TriKE®) and Dual Targeting TriKE® platforms. The company focuses on harnessing natural killer (NK) cells to target cancer. This report covers the quarterly period ended June 30, 2025, and the six months ended June 30, 2025. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,209,000) | $(5,976,000) |
| Net Loss Attributable to Common Stockholders | $(2,294,000) | $(5,976,000) |
| Net Loss Per Share (Basic & Diluted) | $(0.90) | $(3.86) |
| Operating Expenses | $3,445,000 | $6,997,000 |
| Cash and Cash Equivalents (End of Period) | $5,228,000 | $9,249,000 (Total Cash & Restricted) |
| Working Capital | $4,817,000 | $(1,670,000) (Deficit) |
| Net Cash Used in Operating Activities | $(5,216,000) | $(7,699,000) |
| Net Cash Provided by Financing Activities | $6,493,000 | $2,976,000 |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by approximately 51% ($3.55 million) compared to the prior year period. Research and Development (R&D) expenses dropped 43% to $1.46 million, and Selling, General, and Administrative (SG&A) expenses dropped 53% to $1.98 million. This was driven by reduced production costs, scientific research costs, and significant reductions in legal fees.
- Financing Activity: The company raised approximately $5.44 million in net proceeds from the issuance of Series L Convertible Preferred Stock and warrants in May 2025. Additionally, the company received $1.05 million from the exercise of warrants and inducement warrants.
- Liability Reduction: Accounts payable decreased significantly from $3.85 million to $1.37 million, largely due to the settlement of vendor payables through the issuance of stock and warrants, and a $1 million reduction in legal fees recognized as a gain.
- Equity Position: Stockholders' equity moved from a deficit of $(1.67) million at year-end 2024 to a positive balance of $2.86 million as of June 30, 2025, primarily due to the Series L financing and warrant exercises.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states that the company's financial condition raises substantial doubt about its ability to continue as a going concern within one year. The company has no approved products, no revenue, and expects to continue incurring losses. It relies on additional financing to fund operations.
- Product Pipeline:
- GTB-3650: Enrollment for the Phase 1 clinical trial for relapsed/refractory AML and high-risk MDS began in January 2025.
- GTB-5550: Preclinical studies are ongoing for this solid tumor candidate; an IND application is anticipated in Q4 2025.
- GTB-7550: In development for lupus and autoimmune disorders.
- Unusual Items:
- Gain on Settlement: A $998,000 gain was recorded from a legal services firm agreeing to reduce prior year unpaid fees by approximately $1 million.
- Warrant Liability: A $12,000 gain was recorded from the change in fair value of warrant liability.
- Risks:
- Litigation: The company is involved in arbitration with its former CFO (Ohri Matter) and multiple lawsuits regarding convertible notes (TWF Global, Silberfein, DiPietro, Werthman Trust). The company intends to vigorously defend these claims.
- NASDAQ Compliance: The company regained compliance with the Minimum Stockholders' Equity Requirement in June 2025 after previously receiving a deficiency notice. Continued compliance is required to avoid delisting.
Investor Verification Checklist
- Liquidity Runway: Verify if the $5.2 million cash balance is sufficient to fund operations through the next 12 months given the $5.2 million cash burn in the first six months of 2025.
- Series L Terms: Review the full terms of the Series L Convertible Preferred Stock, specifically the 10% cumulative dividend rate, redemption rights, and the full ratchet anti-dilution protection which significantly impacts future dilution.
- Related Party Transactions: Confirm the status of the $598,000 payable to Cytovance Biologics (a related party owning >5% of stock) and the terms of the University of Minnesota research agreements.
- Litigation Exposure: Assess the potential financial impact of the pending lawsuits regarding convertible notes and the arbitration with the former CFO, as these could result in significant cash outflows or equity dilution.
- Warrant Overhang: Note the significant number of outstanding warrants (approx. 16.75 million) and options, which represent substantial potential dilution if exercised.